Abstract
The Parkinson Study Group STEADY-PD III Investigators reported the results of a randomized controlled trial evaluating the effect of isradipine, a dihydropyridine calcium-channel blocker, on clinic...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
